Aurobindo acquires 7 oncology drugs from spectrum for $300 million

Nasdaq-listed Spectrum Pharmaceuticals has carved out its commercial business inclusive of seven marketed oncology injectable products, intellectual property and commercial infrastructure.

from Healthcare/Biotech-Industry-Economic Times http://bit.ly/2HkfYUB
via IFTTT